Randomized controlled study of preoperative intratumoral OK-432 administration for gastric cancer patients

A. Gouchi, S. Fuchimoto, K. Orita, E. Konaga, T. Mannami, S. Okamura, K. Satoh, T. Ohhara, N. Ogawa

Research output: Contribution to journalArticlepeer-review

Abstract

Many BRMs (Biological Response Modifiers) have been used for postoperative chemoimmunotherapy, and their usefulness was also reported. But these results were not satisfactory, and randomized studies were tried. Then we attempted a study to confirm the efficacy of preoperative intratumoral injection of OK- 432 for advanced gastric patients. In all, 395 cases were entered in the study and randomized according to preoperative diagnosis. In these cases, early gastric cancer cases were excluded, 277 cases were evaluable, 145 were preoperative OK-432 injected (group A), and 132 cases were control (group B). The five year survival rate was improved in group A, especially in stage IIIa, n2(+) and negative reaction of PPD. According to multi-valent analysis, the effect of lymph node metastasis, which was one of the important prognostic factors, was lower in group A than in group B. These results suggest that preoperative intra-tumoral OK-432 injection reduced the metastatic rate and improved the postoperative survival rate.

Original languageEnglish
Pages (from-to)50-59
Number of pages10
JournalBiotherapy
Volume10
Issue number1
Publication statusPublished - Mar 4 1996

Keywords

  • Intratumoral injection
  • Medical lymphadenectomy
  • OK-432

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Randomized controlled study of preoperative intratumoral OK-432 administration for gastric cancer patients'. Together they form a unique fingerprint.

Cite this